David S. Ettinger

Active 1976–2024

99
Papers
25,139
Citations
83
h-index
98
i10-index

Citations

Citations per year for David S. Ettinger1979: 3 citations1980: 6 citations1981: 7 citations1982: 14 citations1983: 16 citations1984: 14 citations1985: 15 citations1986: 24 citations1987: 18 citations1988: 26 citations1989: 29 citations1990: 27 citations1991: 40 citations1992: 35 citations1993: 66 citations1994: 89 citations1995: 76 citations1996: 50 citations1997: 48 citations1998: 68 citations1999: 53 citations2000: 44 citations2001: 54 citations2002: 58 citations2003: 50 citations2004: 49 citations2005: 70 citations2006: 64 citations2007: 65 citations2008: 72 citations2009: 75 citations2010: 77 citations2011: 86 citations2012: 69 citations2013: 91 citations2014: 113 citations2015: 100 citations2016: 115 citations2017: 130 citations2018: 117 citations2019: 676 citations2020: 746 citations2021: 711 citations2022: 590 citations2023: 445 citations2024: 864 citations2025: 316 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,494 citing papers, 28.8% of this breakdownChina: 1,680 citing papers, 19.4% of this breakdownItaly: 378 citing papers, 4.4% of this breakdownUnited Kingdom: 332 citing papers, 3.8% of this breakdownJapan: 331 citing papers, 3.8% of this breakdownGermany: 302 citing papers, 3.5% of this breakdownFrance: 291 citing papers, 3.4% of this breakdownCanada: 284 citing papers, 3.3% of this breakdownNetherlands: 221 citing papers, 2.5% of this breakdownSouth Korea: 209 citing papers, 2.4% of this breakdownSpain: 204 citing papers, 2.4% of this breakdownSwitzerland: 170 citing papers, 2% of this breakdown
0%28.8%Other 20.3%

Fields

  • Medicine76.7%
  • Biochemistry, Genetics and Molecular Biology17.1%
  • Immunology and Microbiology1.3%
  • Computer Science0.9%
  • Materials Science0.8%
  • Engineering0.7%
  • Other2.5%

Topics

  • Lung Cancer Treatments and Mutations9.6%
  • Lung Cancer Diagnosis and Treatment9.4%
  • Lung Cancer Research Studies6.3%
  • Cancer Immunotherapy and Biomarkers6.2%
  • Radiomics and Machine Learning in Medical Imaging3.3%
  • Cancer Genomics and Diagnostics2.4%
  • Other62.8%

Coauthors

All papers

Open in search
  1. Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2022 cited by 1,419

  2. NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory J. Riely, Jonathan W. Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2023 cited by 483

  3. Non–Small Cell Lung Cancer, Version 4.2024

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dwight H. Owen, Sandip Pravin Patel, Tejas Patil, Patricio M. Polanco, Jonathan W. Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, Lisa Hang - Journal of the National Comprehensive Cancer Network 2024 cited by 756

  4. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda L. Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2021 cited by 1,006

  5. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , - JAMA Oncology 2020 cited by 489

  6. Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 cited by 431

  7. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2017 cited by 1,325

  8. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2018 cited by 631

  9. The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 198

  10. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Stevenson, Scott J. Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, OCN, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2019 cited by 1,005

  11. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephen B. Baylin, Julie R. Brahmer, Robert B. Scharpf, Patrick M. Forde, Victor E. Velculescu - Nature Cancer 2020 cited by 207

  12. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lynn Tanoue, Betty C. Tong, William D. Travis, Benjamin Wei, Kenneth D. Westover, Stephen C. Yang, Beth McCullough, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2022 cited by 150

  13. Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2018 cited by 190

  14. American Cancer Society lung cancer screening guidelines

    Authors: , , , , , , , , , , , , , , , , , , , - CA A Cancer Journal for Clinicians 2013 cited by 727

  15. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2016 cited by 738

  16. Added Value of Computer-aided CT Image Features for Early Lung Cancer Diagnosis with Small Pulmonary Nodules: A Matched Case-Control Study

    Authors: , , , , , , , , , , , , , , , , - Radiology 2017 cited by 182

  17. Elucidating the Heterogeneity of Immunotherapy Response and Immune-Related Toxicities by Longitudinal ctDNA and Immune Cell Compartment Tracking in Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ali H. Zaidi, Patrick M. Forde, Valsamo Anagnostou - Clinical Cancer Research 2023 cited by 33

  18. NCCN Guidelines Insights: Antiemesis, Version 2.2017

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2017 cited by 248

  19. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Lung Cancer 2019 cited by 114

  20. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

    Authors: , , , , , - Journal of Clinical Oncology 1993 cited by 362

  21. Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, Stephen C. Yang - Journal of the National Comprehensive Cancer Network 2010 cited by 735

  22. Non–Small Cell Lung Cancer, Version 6.2015

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steven E. Schild, Theresa A. Shapiro, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes - Journal of the National Comprehensive Cancer Network 2015 cited by 487

  23. Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2023 cited by 43

  24. Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , - Journal of Thoracic Oncology 2013 cited by 145